Fidelity Investments
KYTX icon

Fidelity Investments’s Kyverna Therapeutics KYTX Stock Holding History

Fidelity Investments’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$856K Buy
96,051
+89,240
+1,310% +$792K ﹤0.01% 3069
2026
Q1 		$58.8K Sell
6,811
-165
-2% -$1.38K ﹤0.01% 4053
2025
Q4 		$65.6K Sell
6,976
-942
-12% -$6.99K ﹤0.01% 3970
2025
Q3 		$47.5K Sell
7,918
-262
-3% -$1.05K ﹤0.01% 3994
2025
Q2 		$25.1K Buy
8,180
+5,787
+242% +$14.3K ﹤0.01% 4203
2025
Q1 		$4.62K Buy
2,393
+784
+49% +$2.32K ﹤0.01% 4729
2024
Q4 		$6.02K Sell
1,609
-5,083
-76% -$24.4K ﹤0.01% 4624
2024
Q3 		$32.7K Buy
+6,692
New +$51.6K ﹤0.01% 3966

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.32B AUM 1.62% 1-Year Est. Return

Fidelity Investments's KYTX Position: Q2 2026 in Review

Fidelity Investments increased its Kyverna Therapeutics (KYTX) stake by 1,310% in Q2 2026, buying an estimated $792K and bringing the position to 96,051 shares worth $856K. The position accounts for ﹤0.01% of the portfolio, ranked #3069.

Fidelity Investments first reported a position in KYTX in Q3 2024 and has held it in 8 quarters since. 120 funds tracked by Wall St. Rank hold KYTX as of Q2 2026.

  • Fidelity Investments held 96,051 shares of Kyverna Therapeutics worth $856K as of Q2 2026.
  • Fidelity Investments bought 89,240 Kyverna Therapeutics shares in Q2 2026, an estimated $792K.
  • Kyverna Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #3069 holding.
  • Fidelity Investments first reported a position in Kyverna Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • 120 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.